Insight Molecular Diagnostics (IMDX) Income towards Parent Company (2015 - 2026)

Insight Molecular Diagnostics (IMDX) has 12 years of Income towards Parent Company data on file, last reported at -$4.4 million in Q1 2026.

• Quarterly Income towards Parent Company rose 35.09% year-over-year to -$4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.2 million (up 20.54% YoY) and the FY2025 annual result came in at -$10.5 million, up 17.21% from the prior year.
• Income towards Parent Company retreated to -$4.4 million in Q1 2026 per IMDX's latest filing, from $17.1 million in the prior quarter.
• The five-year high for Income towards Parent Company was $17.1 million in Q4 2025, with the low at -$33.0 million in Q4 2022.
• Average Income towards Parent Company over 5 years is -$6.1 million, with a median of -$6.9 million recorded in 2022.
• Year-over-year, Income towards Parent Company surged 57.46% in 2023 and tumbled 212.0% in 2024.
• Insight Molecular Diagnostics' Income towards Parent Company stood at -$33.0 million in 2022, then surged by 91.12% to -$2.9 million in 2023, then surged by 601.54% to $14.7 million in 2024, then increased by 16.81% to $17.1 million in 2025, then plunged by 125.74% to -$4.4 million in 2026.
• Business Quant data shows IMDX's Income towards Parent Company at -$4.4 million in Q1 2026, $17.1 million in Q4 2025, and -$11.0 million in Q3 2025.